Welcome to our dedicated page for Mountain Vy Md news (Ticker: MVMDF), a resource for investors and traders seeking the latest updates and insights on Mountain Vy Md stock.
Mountain Valley MD Holdings Inc. reports developments across commercialization of its patented Quicksome™ and Quicksol™ formulation technologies, its licensed Agrarius™ agricultural plant signaling product, and related branded nutraceutical initiatives. News about MVMDF commonly covers nutraceutical product formats, agricultural product evaluations, regional distribution and regulatory work, and applications for husbandry animals and aquatic species.
Company updates also include capital actions such as private placements and shares-for-debt transactions, stock option grants, advisor and board appointments, and shareholder or governance matters tied to its public-company status.
The More Life Company Corp. (CSE: MLCO), formerly Mountain Valley MD Holdings, announced that its common shares will continue to be quoted on the OTCIQ under the new U.S. trading symbol TMLCF, effective at the market open on August 21, 2026.
The company began trading on the Canadian Securities Exchange under its new name and symbol MLCO on August 20, 2026. The More Life Company also introduced a new CUSIP (616536108) and ISIN (CA6165361081). The business focuses on life sciences technologies for agriculture and human health, including Agrarius™, Quicksome™ and Quicksol™ platforms.
The More Life Company Corp. (OTC: MVMDF), formerly Mountain Valley MD Holdings, has completed a corporate name change as part of its rebranding strategy. Subject to final Canadian Securities Exchange processing, common shares are expected to begin trading under the new name and symbol “MLCO” on August 20, 2026. The new CUSIP is 616536108 and the new ISIN is CA6165361081, while the company’s shares will continue to be quoted on the OTCID under MVMDF.
According to the company, share capital, business, assets, liabilities, management and operations remain unchanged. The company also completed a continuance from British Columbia to Ontario corporate law and a short-form amalgamation with its wholly owned subsidiary. A new corporate website, www.themorelife.company, has been launched to present the updated brand and investor information.
Mountain Valley MD (CSE: MVMD, OTC: MVMDF) announced the appointment of five new strategic advisors: Dr. Zach Bush, Erai Beckmann, Mehcad Brooks, Dr. Sanjeev Goel and Eric Zember. They bring experience across clinical and consumer health, regenerative agriculture, media and communications, technology, intellectual property, business development, governance and U.S. capital markets.
The company also granted an aggregate of 3,250,000 stock options to certain consultants and advisors under its Stock Option Plan at an exercise price of $0.075 per share, exercisable for five years with staged vesting over 12 months. Mountain Valley MD continues to focus on implementing, licensing and reselling its Quicksome™, Quicksol™ and Agrarius™ technologies for human, animal and agricultural applications.
Mountain Valley MD (OTC:MVMDF) reported progress advancing its patented Quicksome™ sublingual delivery platform for compounded peptide applications across North and South America. Over six months, the company completed initial Quicksome formulations for peptides including BPC-157, GHK-Cu, KPV, SNAP-8 and retatrutide and is finalizing dosing.
Quicksome aims to deliver needle-free, room‑temperature sublingual tablets for molecules that often require injection and refrigeration. Prior work with tIPV showed 100% preservation of IPV serotype 2 at 40°C for five days. MVMD is pursuing partnerships and licensing with compounding pharmacies, telehealth and wellness channels.
Mountain Valley MD (OTC: MVMDF) appointed nine advisors across health, agriculture, formulation science, and capital markets and granted 15,100,000 stock options at a $0.06 exercise price. Options vest 20% at grant, 30% at six months, and 50% at 12 months, exercisable for five years.
The advisors bring expertise in product formulation, regulatory strategy, commercialization, and capital markets to support peptide and repurposed-therapeutic development.
Summary not available.
Mountain Valley MD (OTC: MVMDF) closed a non‑brokered unit offering and concurrent shares‑for‑debt transactions on April 15, 2026, raising CAD $2,000,000 via 80,000,000 units at CDN $0.025 and issuing 24,647,058 shares to settle CAD $485,000 of debt. Warrants were issued exercisable at CDN $0.08 for 12 months, with acceleration if CSE VWAP ≥ $0.12 for ten consecutive days. Securities are subject to a four‑month and one‑day hold expiring August 15, 2026.
Mountain Valley MD (OTC: MVMDF) announced a strategic non-brokered private placement of units to raise up to CAD $2,000,000 and concurrent shares-for-debt transactions to settle CAD $485,000. The Offering is for up to 80,000,000 Units at CDN $0.025 each; each Unit includes one warrant exercisable at CDN $0.08 for 12 months. The company expects to close in April 2026, subject to CSE approval and customary resale hold periods.
Mountain Valley MD (OTCQB: MVMDF) provided a year-end business update on December 24, 2025, reporting commercialization progress across three platforms: Quicksome nutraceutical delivery, Agrarius agricultural plant signaling, and Quicksol/Soluvec for husbandry and aquaculture.
Key disclosed outcomes include scaled production and retail activity for Quicksome-based nutraceuticals, multiple Agrarius trials showing double-digit yield gains in citrus and row crops, and Soluvec 1% demonstrating nine-month stability but limited royalty revenue to date.
Mountain Valley MD (OTC:MVMDF) reported positive Agrarius agricultural trial results from Brazil and Colombia on December 1, 2025, showing measurable yield and plant‑health gains across multiple crops. Key highlights include a 49% yield increase in Valencia oranges and ~15% (125 boxes/ha) improvement in Hamlin oranges, plus observed reduction in visible HLB symptoms. Potato trials showed 18.49% higher productivity; corn trials reported 14.8% and 11.2% gains. Colombian pasture trials demonstrated improved regrowth and nutritional quality, with final analysis expected in early 2026. The company positions Agrarius for scaled commercialization across citrus, row crops, and forage systems.